Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Last trade$5.58
Day change+$0.205 (+3.81%)
Day range$5.53 – $6.26
Volume19,279
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for TRIB.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for TRIB.
Recent news
Company coverage with links to the original publishers.
Trinity Biotech announced continued execution of its transformation strategy, including commercial leadership strengthening in Europe, rollout of upgraded HbA1c column technology, and expansion of its PrePsia™ patent portfolio to nine patents. However, the company received a Nasdaq delisting notice after failing to maintain the $15 million minimum market value of publicly held shares requirement by the August 18, 2026 deadline. The company intends to request a hearing before a Nasdaq panel and is pursuing strategic initiatives to regain compliance.
Trinity Biotech plc received a non-compliance notice from Nasdaq on February 19, 2026, for failing to maintain the minimum market value of publicly held shares (MVPHS) of $15,000,000 required under Nasdaq Listing Rule 5450(b). The company has 180 calendar days until August 18, 2026, to regain compliance or face potential delisting. The ADSs will continue trading on Nasdaq Global Select Market under the symbol 'TRIB' during this period.
Trinity Biotech plc received a non-compliance notice from Nasdaq on February 11, 2026, for failing to maintain the minimum bid price of $1.00 per share. The company has 180 calendar days until August 10, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. Management is evaluating options to cure the deficiency while the ADSs continue trading on the Nasdaq Global Select Market.
Trinity Biotech collaborates with a bioinformatics company to enhance its EpiCapture prostate cancer test, which uses DNA methylation patterns to monitor disease progression non-invasively.
The global biosensors market is expected to grow from USD 30.04 billion in 2024 to USD 68.72 billion by 2034, with a CAGR of 8.64%. North America dominates the market, while Asia-Pacific shows the fastest growth potential, driven by chronic disease management and technological advancements.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jun 5, 2015
$33.00
Jul 1, 2015
recurring
Jun 6, 2014
$33.00
Jul 1, 2014
recurring
Jun 6, 2013
$30.00
Jul 1, 2013
recurring
Jun 6, 2012
$22.50
Jun 22, 2012
recurring
Jun 7, 2011
$15.00
Jun 23, 2011
unknown
Stock splits
Historical share-structure events and their execution dates.